Arch Aesthetic Plast Surg.  2019 Apr;25(2):73-78. 10.14730/aaps.2019.01655.

Use of Abnobaviscum to treat refractory seroma after breast reconstruction with a latissimus dorsi flap: A case report

Affiliations
  • 1Department of Plastic and Reconstructive Surgery, School of Medicine, Kyungpook National University, Daegu, Korea. lambyang@knu.ac.kr
  • 2Department of Surgery, School of Medicine, Kyungpook National University, Daegu, Korea.

Abstract

In recent years, there has been a notable increase in the rate of refractory donor site seroma, defined as seroma that persists for at least 3 months postoperatively, as the number of breast reconstructions using a latissimus dorsi (LD) musculocutaneous flap has increased. Various factors have been proposed to be related, including smoking, obesity, flap mass, and body weight, and several studies have been conducted to explore treatment methods. Typically, surgical treatment, such as capsulectomy, has been considered for refractory seroma, but in this case report, we describe positive outcomes achieved by using Abnobaviscum to treat three female patients who developed a donor site seroma at least 3 months after breast reconstruction using an LD flap.

Keyword

Abnobaviscum; Latissimus dorsi musculocutaneous flap; Mammaplasty; Seroma

MeSH Terms

Body Weight
Breast*
Female
Humans
Mammaplasty*
Myocutaneous Flap
Obesity
Seroma*
Smoke
Smoking
Superficial Back Muscles*
Tissue Donors
Smoke
Full Text Links
  • AAPS
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
    DB Error: unknown error